Symbols / ALDX Stock $1.68 +1.20% Aldeyra Therapeutics, Inc.

Healthcare • Biotechnology • United States • NCM
ALDX (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Biotechnology
CEO Dr. Todd C. Brady M.D., Ph.D.
Exch · Country NCM · United States
Market Cap 101.34M
Enterprise Value 51.85M
Income -27.37M
Sales —
FCF (ttm) -19.60M
Book/sh 0.70
Cash/sh 1.08
Employees 7
Insider 10d —
IPO May 02, 2014
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E -7.91
PEG —
P/S —
P/B 2.40
P/C —
EV/EBITDA -1.84
EV/Sales —
Quick Ratio 2.67
Current Ratio 2.72
Debt/Eq 36.80
LT Debt/Eq —
EPS (ttm) -0.45
EPS next Y -0.21
EPS Growth —
Revenue Growth —
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2026-08-06
Earnings (prior) 2026-05-07
ROA -22.22%
ROE -51.76%
ROIC —
Gross Margin 0.00%
Oper. Margin 0.00%
Profit Margin 0.00%
Shs Outstand 60.32M
Shs Float 48.70M
Insider Own 3.18%
Instit Own 65.83%
Short Float 12.61%
Short Ratio 4.36
Short Interest 7.36M
52W High 6.17
vs 52W High -72.79%
52W Low 1.07
vs 52W Low 57.01%
Beta 1.15
Impl. Vol. 1.80%
Rel Volume 0.43
Avg Volume 3.06M
Volume 1.31M
Target (mean) $7.60
Tgt Median $9.00
Tgt Low $2.00
Tgt High $13.00
# Analysts 5
Recom Buy
Prev Close $1.66
Price $1.68
Change 1.20%
About

Aldeyra Therapeutics, Inc., a biotechnology company, discovers and develops therapies designed to treat immune-mediated diseases. Its lead product candidate is reproxalap, a reactive aldehyde species (RASP) modulator, which is in Phase III clinical trial for the treatment of dry eye disease and allergic conjunctivitis; and ADX-2191, a dihydrofolate reductase inhibitor for the treatment of primary vitreoretinal lymphoma and retinitis pigmentosa. The company also develops ADX-629, an orally administered RASP modulator that is in Phase 2 clinical trials for the treatment of COVID-19, atopic asthma, psoriasis, and alcohol intoxication. In addition, it develops preclinical RASP platforms, including ADX 248, ADX 246, and other novel RASP modulators for the treatment of various diseases associated with RASP. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was incorporated in 2004 and is based in Lexington, Massachusetts.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$7.60
Mean price target
2. Current target
$1.68
Latest analyst target
3. DCF / Fair value
$-5.85
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$1.68
Low
$2.00
High
$13.00
Mean
$7.60

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-03-18 down HC Wainwright & Co. Buy → Neutral $2
2025-11-10 reit BTIG Buy → Buy $9
2025-05-19 reit HC Wainwright & Co. Buy → Buy $10
2025-04-07 main BTIG Buy → Buy $9
2025-04-04 reit HC Wainwright & Co. Buy → Buy $10
2025-03-03 reit HC Wainwright & Co. Buy → Buy $10
2024-08-09 reit HC Wainwright & Co. Buy → Buy $10
2024-08-02 reit HC Wainwright & Co. Buy → Buy $10
2024-05-06 reit Oppenheimer Outperform → Outperform $10
2024-05-06 reit HC Wainwright & Co. Buy → Buy $10
2024-04-03 up Oppenheimer Perform → Outperform $10
2023-10-17 main Citigroup Buy → Buy $8
2023-10-17 down Oppenheimer Outperform → Perform —
2023-08-09 reit Oppenheimer Outperform → Outperform $14
2023-06-30 reit HC Wainwright & Co. Buy → Buy $15
2023-06-22 reit HC Wainwright & Co. Buy → Buy $15
2023-06-16 reit HC Wainwright & Co. Buy → Buy $15
2023-06-01 main Citigroup Buy → Buy $25
2023-05-05 reit HC Wainwright & Co. — → Buy $15
2023-03-10 main Citigroup Buy → Buy $28
News
RSS: Latest ALDX news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-03-19 DOUGLAS RICHARD H Director — 70,000 $1.83 $128,100
2026-03-18 ALFIERI MICHAEL L Chief Financial Officer — 5,000 $1.42 $7,100
2025-08-13 ALFIERI MICHAEL L Chief Financial Officer — 2,500 $5.30 $13,250
2025-08-11 MACHATHA STEPHEN Officer — 22,073 $5.15 $113,713
2025-04-03 PERCEPTIVE ADVISORS L L C Beneficial Owner of more than 10% of a Class of Security — 3,400,000 $1.42 $4,828,000
2024-08-12 MACHATHA STEPHEN Officer — 16,041 $4.74 $75,975
2024-08-12 GREENBERG BRUCE Chief Financial Officer — 10,834 $4.74 $51,313
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
0.00
0.00
0.00
0.00
Operating Revenue
0.00
0.00
0.00
0.00
Operating Expense
35.27
-41.34%
60.12
+40.48%
42.79
-31.73%
62.68
Research And Development
25.66
-46.78%
48.22
+63.70%
29.46
-37.73%
47.31
Selling General And Administration
9.60
-19.26%
11.89
-10.82%
13.34
-13.26%
15.37
General And Administrative Expense
9.60
-19.26%
11.89
-10.82%
13.34
-13.26%
15.37
Other Gand A
9.60
-19.26%
11.89
-10.82%
13.34
-13.26%
15.37
Total Expenses
35.27
-41.34%
60.12
+40.48%
42.79
-31.73%
62.68
Operating Income
-35.27
+41.34%
-60.12
-40.48%
-42.79
+31.73%
-62.68
Total Operating Income As Reported
-35.27
+41.34%
-60.12
-40.48%
-42.79
+31.73%
-62.68
EBITDA
-31.69
+40.96%
-53.68
-52.45%
-35.21
+41.39%
-60.07
Normalized EBITDA
-31.69
+40.96%
-53.68
-52.45%
-35.21
+41.39%
-60.07
Reconciled Depreciation
0.25
+0.95%
0.25
-5.01%
0.26
+1.57%
0.26
EBIT
-31.94
+40.77%
-53.93
-52.03%
-35.47
+41.21%
-60.33
Total Unusual Items
—
—
—
—
Total Unusual Items Excluding Goodwill
—
—
—
—
Special Income Charges
—
—
—
—
Net Income
-33.85
+39.40%
-55.85
-48.77%
-37.54
+39.47%
-62.02
Pretax Income
-33.85
+39.40%
-55.85
-48.77%
-37.54
+39.47%
-62.02
Net Non Operating Interest Income Expense
1.42
-66.74%
4.27
-18.78%
5.25
+701.34%
0.66
Interest Expense Non Operating
1.91
-1.09%
1.93
-7.01%
2.07
+22.27%
1.69
Net Interest Income
1.42
-66.74%
4.27
-18.78%
5.25
+701.34%
0.66
Interest Expense
1.91
-1.09%
1.93
-7.01%
2.07
+22.27%
1.69
Interest Income Non Operating
3.32
-46.32%
6.19
-15.45%
7.32
+211.69%
2.35
Interest Income
3.32
-46.32%
6.19
-15.45%
7.32
+211.69%
2.35
Tax Provision
—
—
—
—
Tax Rate For Calcs
0.00
0.00
0.00
0.00
Tax Effect Of Unusual Items
0.00
0.00
0.00
0.00
Net Income Including Noncontrolling Interests
-33.85
+39.40%
-55.85
-48.77%
-37.54
+39.47%
-62.02
Net Income From Continuing Operation Net Minority Interest
-33.85
+39.40%
-55.85
-48.77%
-37.54
+39.47%
-62.02
Net Income From Continuing And Discontinued Operation
-33.85
+39.40%
-55.85
-48.77%
-37.54
+39.47%
-62.02
Net Income Continuous Operations
-33.85
+39.40%
-55.85
-48.77%
-37.54
+39.47%
-62.02
Normalized Income
-33.85
+39.40%
-55.85
-48.77%
-37.54
+39.47%
-62.02
Net Income Common Stockholders
-33.85
+39.40%
-55.85
-48.77%
-37.54
+39.47%
-62.02
Diluted EPS
-0.56
+40.43%
-0.94
-46.87%
-0.64
+39.62%
-1.06
Basic EPS
-0.56
+40.43%
-0.94
-46.87%
-0.64
+39.62%
-1.06
Basic Average Shares
60.06
+0.96%
59.48
+0.92%
58.94
+0.92%
58.41
Diluted Average Shares
60.06
+0.96%
59.48
+0.92%
58.94
+0.92%
58.41
Diluted NI Availto Com Stockholders
-33.85
+39.40%
-55.85
-48.77%
-37.54
+39.47%
-62.02
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Assets
72.06
-31.11%
104.61
-29.48%
148.33
-18.18%
181.29
Current Assets
71.78
-31.03%
104.07
-29.59%
147.81
-18.35%
181.02
Cash Cash Equivalents And Short Term Investments
70.04
-30.76%
101.15
-29.18%
142.82
-18.06%
174.30
Cash And Cash Equivalents
70.04
+28.45%
54.53
-61.82%
142.82
-1.11%
144.42
Cash Equivalents
40.47
+31.44%
30.79
+115.15%
14.31
+54.43%
9.27
Cash Financial
29.57
+24.58%
23.73
-81.53%
128.51
-4.91%
135.15
Other Short Term Investments
0.00
-100.00%
46.62
0.00
-100.00%
29.88
Receivables
—
—
0.00
-100.00%
3.24
Other Receivables
—
—
—
3.24
Prepaid Assets
0.41
-0.22%
0.41
+19.89%
0.34
-21.25%
0.43
Current Deferred Assets
1.04
-52.84%
2.21
-50.45%
4.46
+71.34%
2.61
Other Current Assets
0.29
-3.06%
0.30
+64.43%
0.18
-58.63%
0.44
Total Non Current Assets
0.28
-48.36%
0.53
+3.41%
0.52
+92.36%
0.27
Net PPE
0.28
+3.34%
0.27
-48.32%
0.52
+92.36%
0.27
Gross PPE
0.28
+3.34%
0.27
-48.32%
0.52
+92.36%
0.27
Other Properties
0.28
+3.34%
0.27
-48.32%
0.52
+92.36%
0.27
Non Current Deferred Assets
0.00
-100.00%
0.27
0.00
—
Total Liabilities Net Minority Interest
27.81
-17.24%
33.60
+17.77%
28.53
-5.78%
30.28
Current Liabilities
27.81
+49.50%
18.60
-16.43%
22.26
+44.92%
15.36
Payables And Accrued Expenses
2.01
-74.82%
7.97
+110.36%
3.79
-63.51%
10.38
Payables
0.16
-12.19%
0.18
-86.51%
1.34
+901.35%
0.13
Accounts Payable
0.16
-12.19%
0.18
-86.51%
1.34
+901.35%
0.13
Current Accrued Expenses
1.85
-76.27%
7.79
+217.95%
2.45
-76.10%
10.24
Pensionand Other Post Retirement Benefit Plans Current
4.27
-1.39%
4.33
+40.33%
3.09
-19.20%
3.82
Current Debt And Capital Lease Obligation
15.53
+5025.42%
0.30
-98.03%
15.39
+1225.18%
1.16
Current Debt
15.25
+48509.05%
0.03
-99.79%
15.15
+1561.24%
0.91
Other Current Borrowings
15.25
+48509.05%
0.03
-99.79%
15.15
+1561.24%
0.91
Current Capital Lease Obligation
0.28
+3.28%
0.27
+13.57%
0.24
-4.04%
0.25
Current Deferred Liabilities
6.00
+0.00%
6.00
0.00
—
Current Deferred Revenue
6.00
+0.00%
6.00
0.00
—
Total Non Current Liabilities Net Minority Interest
0.00
-100.00%
15.00
+139.17%
6.27
-57.97%
14.92
Long Term Debt And Capital Lease Obligation
—
15.00
+5422.20%
0.27
-98.18%
14.92
Long Term Debt
—
15.00
—
14.92
Long Term Capital Lease Obligation
—
0.00
-100.00%
0.27
0.00
Non Current Deferred Liabilities
—
0.00
-100.00%
6.00
0.00
Non Current Deferred Revenue
—
0.00
-100.00%
6.00
0.00
Stockholders Equity
44.25
-37.68%
71.00
-40.73%
119.80
-20.67%
151.01
Common Stock Equity
44.25
-37.68%
71.00
-40.73%
119.80
-20.67%
151.01
Capital Stock
0.06
+0.86%
0.06
+0.76%
0.06
+1.09%
0.06
Common Stock
0.06
+0.86%
0.06
+0.76%
0.06
+1.09%
0.06
Preferred Stock
0.00
0.00
0.00
0.00
Share Issued
60.16
+0.86%
59.65
+0.76%
59.20
+1.09%
58.56
Ordinary Shares Number
60.16
+0.86%
59.65
+0.76%
59.20
+1.09%
58.56
Additional Paid In Capital
528.15
+1.37%
521.02
+1.37%
513.99
+1.23%
507.77
Retained Earnings
-483.96
-7.52%
-450.11
-14.17%
-394.26
-10.52%
-356.72
Gains Losses Not Affecting Retained Earnings
0.00
-100.00%
0.04
0.00
+100.00%
-0.10
Other Equity Adjustments
—
0.04
—
-0.10
Total Equity Gross Minority Interest
44.25
-37.68%
71.00
-40.73%
119.80
-20.67%
151.01
Total Capitalization
44.25
-48.55%
86.00
-28.21%
119.80
-27.80%
165.93
Working Capital
43.97
-48.55%
85.47
-31.92%
125.55
-24.21%
165.66
Invested Capital
59.50
-30.84%
86.04
-36.24%
134.94
-19.12%
166.84
Total Debt
15.53
+1.48%
15.30
-2.26%
15.66
-2.65%
16.08
Capital Lease Obligations
0.28
+3.28%
0.27
-46.82%
0.51
+104.93%
0.25
Net Tangible Assets
44.25
-37.68%
71.00
-40.73%
119.80
-20.67%
151.01
Tangible Book Value
44.25
-37.68%
71.00
-40.73%
119.80
-20.67%
151.01
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-33.35
+22.83%
-43.21
-42.48%
-30.33
+46.46%
-56.64
Cash Flow From Continuing Operating Activities
-33.35
+22.83%
-43.21
-42.48%
-30.33
+46.46%
-56.64
Net Income From Continuing Operations
-33.85
+39.40%
-55.85
-48.77%
-37.54
+39.47%
-62.02
Depreciation Amortization Depletion
0.25
+0.95%
0.25
-5.01%
0.26
+1.57%
0.26
Depreciation And Amortization
0.25
+0.95%
0.25
-5.01%
0.26
+1.57%
0.26
Other Non Cash Items
0.22
+23.08%
0.18
-49.94%
0.35
+6.96%
0.33
Stock Based Compensation
6.09
-23.60%
7.97
+38.60%
5.75
-30.60%
8.29
Asset Impairment Charge
0.27
0.00
—
—
Deferred Tax
—
—
—
—
Deferred Income Tax
—
—
—
—
Change In Working Capital
-5.18
-187.57%
5.91
+586.64%
0.86
+125.00%
-3.44
Change In Prepaid Assets
1.18
-42.94%
2.07
+19.09%
1.73
+146.14%
-3.76
Change In Payables And Accrued Expense
-6.36
-265.25%
3.85
+155.97%
-6.87
-2273.11%
0.32
Change In Accrued Expense
-6.34
-226.59%
5.00
+161.95%
-8.08
-771.84%
1.20
Change In Payable
-0.02
+98.10%
-1.16
-196.11%
1.20
+235.93%
-0.89
Change In Account Payable
-0.02
+98.10%
-1.16
-196.11%
1.20
+235.93%
-0.89
Change In Other Working Capital
—
—
6.00
—
Investing Cash Flow
47.74
+206.28%
-44.92
-249.72%
30.00
+200.15%
-29.95
Cash Flow From Continuing Investing Activities
47.74
+206.28%
-44.92
-249.72%
30.00
+200.15%
-29.95
Net PPE Purchase And Sale
—
—
0.00
+100.00%
-0.02
Purchase Of PPE
—
—
0.00
+100.00%
-0.02
Capital Expenditure
—
—
—
-0.02
Net Investment Purchase And Sale
47.74
+206.28%
-44.92
-249.72%
30.00
+200.21%
-29.94
Purchase Of Investment
-40.26
+58.45%
-96.92
0.00
+100.00%
-92.94
Sale Of Investment
88.00
+69.23%
52.00
+73.33%
30.00
-52.38%
63.00
Financing Cash Flow
1.12
+755.43%
-0.17
+86.50%
-1.27
-204.11%
1.22
Cash Flow From Continuing Financing Activities
1.12
+755.43%
-0.17
+86.50%
-1.27
-204.11%
1.22
Net Issuance Payments Of Debt
0.00
+100.00%
-0.29
+71.94%
-1.04
0.00
Repayment Of Debt
0.00
+100.00%
-0.29
+71.94%
-1.04
0.00
Long Term Debt Payments
0.00
+100.00%
-0.29
+71.94%
-1.04
0.00
Net Long Term Debt Issuance
0.00
+100.00%
-0.29
+71.94%
-1.04
0.00
Net Common Stock Issuance
—
—
—
0.00
Proceeds From Stock Option Exercised
1.12
+189.32%
0.39
+27.23%
0.31
-74.98%
1.22
Net Other Financing Charges
—
-0.27
+49.85%
-0.53
—
Changes In Cash
15.51
+117.57%
-88.30
-5431.12%
-1.60
+98.13%
-85.37
Beginning Cash Position
54.53
-61.82%
142.82
-1.11%
144.42
-37.15%
229.79
End Cash Position
70.04
+28.45%
54.53
-61.82%
142.82
-1.11%
144.42
Free Cash Flow
-33.35
+22.83%
-43.21
-42.48%
-30.33
+46.47%
-56.65
Interest Paid Supplemental Data
1.69
-3.74%
1.75
+3.03%
1.70
+27.17%
1.34
Amortization Of Securities
-1.15
+31.21%
-1.67
-11390.74%
-0.01
+69.22%
-0.05
Common Stock Issuance
—
—
—
0.00
Issuance Of Capital Stock
—
—
—
0.00
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category